Prachee Singh, PA-C

Prachee Singh practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Prachee Singh's NPI, 1245316819, was assigned on October 27, 2006. Prachee Singh holds Texas license PA03293.

Prachee Singh's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Prachee Singh's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Prachee Singh practices. Vendor and product names are available with a free account.

Physician assistant is Prachee Singh's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Prachee Singh is licensed in Texas.

CMS data shows 149 Medicare services from Prachee Singh across 3 procedure codes in 2024, for 147 Medicare patients. Medicare paid $7,120 for them.

CMS counts 147 Medicare patients who saw Prachee Singh in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Prachee Singh's median patient age at 73, with 50% women.

In 2024, Prachee Singh wrote 264 Medicare Part D claims for 85 patients. 92% of them were for generic drugs. CMS names the drug for 176 of them, across 8 drugs with 11 or more claims each, at $8,977 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Prachee Singh for performance year 2024, reported as part of a group. Prachee Singh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Prachee Singh as offering telehealth.

CMS Open Payments shows 3 general payments to Prachee Singh from 2 drug and device companies from 2024 to 2025. Education make up the largest share, 61% of the total. Incyte Corporation paid the most, $130.